TY - JOUR
T1 - Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes
AU - Cooperberg, Benjamin A.
AU - Breckenridge, Suzanne M.
AU - Arbelaez, Ana Maria
AU - Cryer, Philip E.
PY - 2008/12
Y1 - 2008/12
N2 - OBJECTIVE- Bedtime administration of 5.0 mg of the β 2- adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes. We tested the hypothesis that 2.5 mg terbutaline prevents nocturnal hypoglycemia without causing morning hyperglycemia. RESEARCH DESIGN AND METHODS- This was a randomized double-blind crossover pilot study (placebo, 2.5 mg terbutaline, and 5.0 mg terbutaline) in 15 patients with type 1 diabetes. RESULTS- Mean ± SE nadir nocturnal plasma glucose concentrations were 87 ± 14 mg/dl following placebo, 100 ± 14 mg/dl following 2.5 mg terbutaline, and 122 ± 13 mg/dl following 5.0 mg terbutaline (p < 0.05 vs. placebo). Nadir levels were <50 mg/dl in 5, 2, and 0 patients (p < 0.05 vs. placebo), respectively. Morning levels were 113 ± 18, 127 ± 17, and 183 ± 19 mg/dl (p < 0.02 vs. placebo), respectively. CONCLUSIONS- Terbutaline may be shown to be effective and safe in the prevention of nocturnal hypoglycemia in type 1 diabetes in a suitably powered randomized controlled trial.
AB - OBJECTIVE- Bedtime administration of 5.0 mg of the β 2- adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes. We tested the hypothesis that 2.5 mg terbutaline prevents nocturnal hypoglycemia without causing morning hyperglycemia. RESEARCH DESIGN AND METHODS- This was a randomized double-blind crossover pilot study (placebo, 2.5 mg terbutaline, and 5.0 mg terbutaline) in 15 patients with type 1 diabetes. RESULTS- Mean ± SE nadir nocturnal plasma glucose concentrations were 87 ± 14 mg/dl following placebo, 100 ± 14 mg/dl following 2.5 mg terbutaline, and 122 ± 13 mg/dl following 5.0 mg terbutaline (p < 0.05 vs. placebo). Nadir levels were <50 mg/dl in 5, 2, and 0 patients (p < 0.05 vs. placebo), respectively. Morning levels were 113 ± 18, 127 ± 17, and 183 ± 19 mg/dl (p < 0.02 vs. placebo), respectively. CONCLUSIONS- Terbutaline may be shown to be effective and safe in the prevention of nocturnal hypoglycemia in type 1 diabetes in a suitably powered randomized controlled trial.
UR - http://www.scopus.com/inward/record.url?scp=64349116234&partnerID=8YFLogxK
U2 - 10.2337/dc08-0520
DO - 10.2337/dc08-0520
M3 - Article
C2 - 18782903
AN - SCOPUS:64349116234
SN - 0149-5992
VL - 31
SP - 2271
EP - 2272
JO - Diabetes care
JF - Diabetes care
IS - 12
ER -